Axsome Therapeutics (AXSM) News Today $90.73 +0.99 (+1.10%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Franklin Resources Inc. Raises Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM)Franklin Resources Inc. increased its stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 47.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 160,534 shares of the company's stock after purchasing an additionaDecember 21 at 4:46 AM | marketbeat.comGeode Capital Management LLC Grows Stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM)Geode Capital Management LLC lifted its stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 2.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 908,459 shares of the company's stock after purDecember 21 at 4:09 AM | marketbeat.comBarclays PLC Buys 45,509 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM)Barclays PLC grew its position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 279.6% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 61,785 shares of the company's stock after buying an additionDecember 21 at 3:56 AM | marketbeat.comAxsome Therapeutics, Inc. (NASDAQ:AXSM) Receives Average Recommendation of "Buy" from BrokeragesShares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Get Free Report) have earned a consensus rating of "Buy" from the fourteen analysts that are covering the company, Marketbeat.com reports. Fourteen research analysts have rated the stock with a buy recommendation. The average 12-month price objectDecember 21 at 3:03 AM | marketbeat.comAxsome Therapeutics (AXSM) Gets a Buy from Mizuho SecuritiesDecember 20 at 9:45 PM | markets.businessinsider.comAxsome Therapeutics (NASDAQ:AXSM) Trading 4% Higher - Time to Buy?Axsome Therapeutics (NASDAQ:AXSM) Shares Up 4% - Here's What HappenedDecember 17, 2024 | marketbeat.comAxsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Sold by State Street CorpState Street Corp reduced its stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 2.3% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 916,808 shares of the company's stock after selling 21,695 shares duDecember 17, 2024 | marketbeat.comAxsome Therapeutics, Inc. (NASDAQ:AXSM) Sees Significant Drop in Short InterestAxsome Therapeutics, Inc. (NASDAQ:AXSM - Get Free Report) saw a significant decrease in short interest in November. As of November 30th, there was short interest totalling 7,080,000 shares, a decrease of 7.9% from the November 15th total of 7,690,000 shares. Based on an average daily volume of 459,900 shares, the days-to-cover ratio is presently 15.4 days.December 16, 2024 | marketbeat.comAxsome Therapeutics' (AXSM) "Overweight" Rating Reaffirmed at Cantor FitzgeraldDecember 15, 2024 | americanbankingnews.comStrong Commercial Performance and Promising Growth Potential of Axsome Therapeutics’ Auvelity Fuels Buy RatingDecember 14, 2024 | markets.businessinsider.comCaptrust Financial Advisors Buys New Shares in Axsome Therapeutics, Inc. (NASDAQ:AXSM)Captrust Financial Advisors purchased a new stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 5,722 shares of the company's stock,December 13, 2024 | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $4.29 Million Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM)UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lowered its position in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 15.1% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 47,714 shares ofDecember 13, 2024 | marketbeat.comWellington Management Group LLP Buys 8,125 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM)Wellington Management Group LLP boosted its stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 1.1% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 742,745 shares of the companDecember 11, 2024 | marketbeat.comPositive Outlook for Axsome Therapeutics: Buy Rating Backed by Promising AXS-05 ProspectsDecember 10, 2024 | markets.businessinsider.comAxsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Purchased by BNP Paribas Financial MarketsBNP Paribas Financial Markets grew its stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 71.7% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 13,733 shares of the company's stock after buying an additional 5December 10, 2024 | marketbeat.comAxsome Therapeutics: Promising Growth Trajectory Justifies Buy Rating Amidst Auvelity’s Commercial SuccessDecember 8, 2024 | markets.businessinsider.comZacks Research Issues Pessimistic Forecast for AXSM EarningsAxsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - Stock analysts at Zacks Research reduced their FY2024 earnings estimates for Axsome Therapeutics in a research report issued on Tuesday, December 3rd. Zacks Research analyst R. Department now forecasts that the company will post earnings ofDecember 6, 2024 | marketbeat.comFmr LLC Raises Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM)Fmr LLC lifted its holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 20.6% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,088,087 shares of the company'sDecember 6, 2024 | marketbeat.comAxsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Sold by RTW Investments LPRTW Investments LP reduced its position in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 9.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,189,557 shares of the company's stock after sellingDecember 5, 2024 | marketbeat.comCharles Schwab Investment Management Inc. Buys 12,778 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM)Charles Schwab Investment Management Inc. increased its stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 4.1% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 322,596 shares of the company's stock after purchasing an addiDecember 5, 2024 | marketbeat.comErste Asset Management GmbH Buys Shares of 11,000 Axsome Therapeutics, Inc. (NASDAQ:AXSM)Erste Asset Management GmbH purchased a new position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 11,000 shares of the companyDecember 4, 2024 | marketbeat.comHighVista Strategies LLC Lowers Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM)HighVista Strategies LLC reduced its stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 33.2% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 41,542 shares of the compaDecember 3, 2024 | marketbeat.comPDT Partners LLC Makes New $1.05 Million Investment in Axsome Therapeutics, Inc. (NASDAQ:AXSM)PDT Partners LLC purchased a new stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 11,701 shares of the company's stock, valueDecember 2, 2024 | marketbeat.comFred Alger Management LLC Invests $851,000 in Axsome Therapeutics, Inc. (NASDAQ:AXSM)Fred Alger Management LLC purchased a new stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 9,466 shares of the company's stock, valued atDecember 2, 2024 | marketbeat.comBellevue Group AG Sells 149,352 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM)Bellevue Group AG reduced its stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 28.9% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 367,181 shares of the company's stock after selling 149,3December 1, 2024 | marketbeat.comBuy Recommendation for Axsome Therapeutics Driven by Auvelity’s Strong Market Performance and Growth PotentialNovember 30, 2024 | markets.businessinsider.comEventide Asset Management LLC Has $74.40 Million Stock Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM)Eventide Asset Management LLC reduced its position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 11.8% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 827,887 shares of the company's stock after selling 110,827 shNovember 29, 2024 | marketbeat.comFORA Capital LLC Acquires Shares of 11,058 Axsome Therapeutics, Inc. (NASDAQ:AXSM)FORA Capital LLC bought a new position in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 11,058 shares of the company's stock, valued at approximatelyNovember 29, 2024 | marketbeat.comAnalysts Are Bullish on Top Healthcare Stocks: Axsome Therapeutics (AXSM), Madrigal Pharmaceuticals (MDGL)November 28, 2024 | markets.businessinsider.comWilliam Blair Issues Pessimistic Forecast for AXSM EarningsAxsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - Research analysts at William Blair reduced their Q4 2025 earnings per share estimates for shares of Axsome Therapeutics in a report issued on Tuesday, November 26th. William Blair analyst M. Minter now forecasts that the company will earn $0November 28, 2024 | marketbeat.comAxsome Therapeutics (NASDAQ:AXSM) Stock Quotes, Forecast and News SummaryNovember 28, 2024 | benzinga.comCynosure Group LLC Invests $713,000 in Axsome Therapeutics, Inc. (NASDAQ:AXSM)Cynosure Group LLC bought a new stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 7,930 shares of the company's stock, valued at approximately $713,000. Other hedge fundsNovember 28, 2024 | marketbeat.comAxsome Therapeutics (NASDAQ:AXSM) Stock, Insider Trading ActivityNovember 28, 2024 | benzinga.comAxsome Therapeutics (NASDAQ:AXSM) Stock, Earnings Estimates, EPS, And RevenueNovember 28, 2024 | benzinga.comAxsome Therapeutics (AXSM) Gets a Buy from RBC CapitalNovember 28, 2024 | markets.businessinsider.comIntech Investment Management LLC Purchases New Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM)Intech Investment Management LLC purchased a new stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) during the third quarter, according to its most recent filing with the SEC. The firm purchased 10,941 shares of the company's stock, valued at approximately $983,000. A number of other heNovember 28, 2024 | marketbeat.comPositive Outlook on Axsome Therapeutics Driven by Promising Clinical Trial Results and Long-term Growth PotentialNovember 27, 2024 | markets.businessinsider.comTruist Financial Sticks to Its Buy Rating for Axsome Therapeutics (AXSM)November 27, 2024 | markets.businessinsider.comFY2024 Earnings Forecast for AXSM Issued By HC WainwrightAxsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - Investment analysts at HC Wainwright lifted their FY2024 EPS estimates for shares of Axsome Therapeutics in a note issued to investors on Monday, November 25th. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn ($November 27, 2024 | marketbeat.comAxsome Therapeutics eyes approval after Phase III narcolepsy winNovember 26, 2024 | yahoo.comAxsome Therapeutics' (NASDAQ:AXSM) growing losses don't faze investors as the stock ascends 5.5% this past weekNovember 26, 2024 | uk.finance.yahoo.comAxsome reports positive Phase 3 data for AXS-12 for narcolepsyNovember 26, 2024 | msn.comAxsome Therapeutics announces AXS-12 achieves primary endpoint in ENCORENovember 26, 2024 | markets.businessinsider.comLoomis Sayles & Co. L P Acquires 29,497 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM)Loomis Sayles & Co. L P grew its position in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 11.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 298,586 shares of the company's stock afterNovember 26, 2024 | marketbeat.comAxsome Therapeutics, Inc. (NASDAQ:AXSM) Receives Consensus Rating of "Buy" from BrokeragesShares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Get Free Report) have been assigned a consensus rating of "Buy" from the fourteen analysts that are currently covering the firm, MarketBeat reports. Fourteen analysts have rated the stock with a buy rating. The average 12-month price objective amoNovember 26, 2024 | marketbeat.comAxsome Therapeutics (NASDAQ:AXSM) Receives "Buy" Rating from HC WainwrightHC Wainwright reissued a "buy" rating and set a $180.00 price objective on shares of Axsome Therapeutics in a research note on Monday.November 25, 2024 | marketbeat.comPositive Prescription Trends and Sales Expansion Drive Buy Rating for Axsome TherapeuticsNovember 25, 2024 | markets.businessinsider.comEagle Asset Management Inc. Sells 15,854 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM)Eagle Asset Management Inc. decreased its position in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 16.1% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 82,791 shares of the company'sNovember 25, 2024 | marketbeat.comLandscape Capital Management L.L.C. Takes Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM)Landscape Capital Management L.L.C. purchased a new position in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 6,513 shares of the company's stock, valNovember 24, 2024 | marketbeat.comB. Metzler seel. Sohn & Co. Holding AG Takes $830,000 Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM)B. Metzler seel. Sohn & Co. Holding AG bought a new position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) in the third quarter, according to the company in its most recent filing with the SEC. The firm bought 9,241 shares of the company's stock, valued at approximately $830,00November 24, 2024 | marketbeat.com Get Axsome Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AXSM and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Humiliated: Demo of Elon’s Tech Proves They’re Wrong (Ad)Elon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it. Click here to watch this demo and decide for yourself. AXSM Media Mentions By Week AXSM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AXSM News Sentiment▼1.320.60▲Average Medical News Sentiment AXSM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AXSM Articles This Week▼107▲AXSM Articles Average Week Get Axsome Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AXSM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies BGNE News UTHR News VTRS News RPRX News SMMT News GMAB News INSM News BMRN News RDY News SRPT News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AXSM) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Axsome Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Axsome Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
